FDC Ltd (FDC) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by FDC Ltd on NSE and BSE, with an AI summary of each filing.
This is to inform that the Company has received favourable orders from the Assistant Commissioner of Income Tax, Mumbai, for AY 2016-17.
Others (Uncategorized) · 04 Nov 2026, 9:46 pm
FDC Limited Secures ₹14.20 Crore Tax Refund for AY 2016-17 FDC Limited received an order on 3rd Nov'26 from the Assistant Commissioner of Income Tax, Mumbai, giving effect to a favourable CIT(A) order dated 29th Sep'26 for AY 2016-17. The appeal resolved disallowances concerning publicity expenses and Section 14A, determining an aggregate tax refund of ₹14.20 Cr. The interest income component included in the refund amount will be recognized in the company's Statement of Profit and Loss.
This is to inform that the Company has received favourable orders from the Assistant Commissioner of Income Tax, Mumbai, for AY 2014-15 and AY 2012-13.
Others (Uncategorized) · 01 Nov 2026, 1:09 am
FDC Receives Favourable Income Tax Orders Determining ₹37.22 Crore Aggregate Refund FDC Limited received favourable appellate orders from CIT(A) for AY 2012-13 and AY 2014-15 regarding disallowances related to publicity expenses and deductions under section 35(2AB). Giving effect to these orders, the jurisdictional Assessing Officer determined an aggregate tax refund of ₹37.22 Cr via orders received on 30th Oct'26 and 31st Oct'26. Consequently, the interest income component included within the total refund amount will be credited directly to the company's Statement of Profit and Loss as other income.
Sundae Capital Advisors Private Limited ("Manager to the Offer") has submitted to BSE a copy of Public Announcement for the attention of Equity Shareholders / Beneficial Owners of the Equity ....
Others (Uncategorized) · 29 Oct 2026, 6:46 pm
FDC Limited Approves ₹120 Crore Share Buyback via Tender Offer FDC Limited's board approved a buyback of up to 24,00,000 equity shares (1.47% of total equity) at ₹500 per share via a tender offer, aggregating up to ₹120.00 Cr. The offer price represents a premium of ~45.5% over closing prices on 19th Oct'26. The buyback constitutes 4.84% standalone and 4.87% consolidated paid-up capital and free reserves as of 31st Mar'26. The record date is set for 13th Nov'26, with 15% reserved for small shareholders. Promoter and Promoter Group intend to participate.
Newspaper advertisement in respect of the Buyback of Shares
Others (Uncategorized) · 29 Oct 2026, 6:39 pm
FDC Limited Announces ₹120 Crore Share Buyback via Tender Offer FDC Limited's Board approved a buyback of up to 24,00,000 equity shares (1.47% of total equity) at ₹500 per share via a tender offer route, aggregating up to ₹120.00 crore. The buyback represents 4.84% and 4.87% of standalone and consolidated net worth, respectively, as of 31st Mar'26. The offer price reflects a ~45.5% premium over closing prices on 19th Oct'26. The record date is fixed for 13th Nov'26, with a 15% reservation allocated for small shareholders. Promoters intend to participate.
The Board has approved the proposal of Buyback of equity shares of the company.
Others (Uncategorized) · 28 Oct 2026, 11:04 pm
FDC Approves Share Buyback Worth Up To ₹120 Crore Via Tender Offer FDC Limited's Board approved a share buyback of up to 24,00,000 equity shares (1.47% of total paid-up equity capital) at ₹500 per share via the tender offer route, for an aggregate consideration not exceeding ₹120.00 crore. The offer size represents 4.84% and 4.87% of standalone and consolidated net worth, respectively, as of 31st Mar'26. The record date is set for 13th Nov'26. Promoters have indicated their intention to participate, with 15% of the offer reserved for small shareholders.
The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026
Financial Result · 28 Oct 2026, 1:44 am
The Board of Directors, at its Meeting held today, has approved the Buyback of Equity Shares. The record date for the same is November 13, 2026.
Others · 28 Oct 2026, 1:21 am
FDC Approves Rs 120 Crore Share Buyback and Reports Q2 Financial Results FDC Limited's board approved a share buyback of up to 24,00,000 equity shares (1.47% of total paid-up capital) at Rs 500 per share via the tender offer route, aggregating up to Rs 120.00 crore, with the record date set for 13th Nov'26. For Q2 ended 30th Sep'26, consolidated revenue from operations rose 20.95% YoY to Rs 572.14 crore from Rs 473.03 crore. Consolidated net profit for the quarter surged 72.93% YoY to Rs 49.06 crore compared to Rs 28.37 crore in the prior-year period.
The Board Has Decided November 13, 2026, as the Record Date For the buyback Offer.
Others (Uncategorized) · 28 Oct 2026, 1:09 am
FDC Approves ₹120 Crore Share Buyback and Reports Q2 FY27 Results FDC Limited's board approved a share buyback of up to 24.00 lakh equity shares (1.47% of total equity) at ₹500 per share via a tender offer, totaling up to ₹120.00 crore, setting the record date as 13th Nov'26. For Q2 ended 30th Sep'26, consolidated revenue from operations rose 20.95% YoY to ₹572.14 crore from ₹473.03 crore, while net profit grew 72.93% YoY to ₹49.06 crore compared to ₹28.37 crore. Diluted EPS for the quarter stood at ₹3.01.
Press Release Q2 FY 2026-27 Results.
Press Release · 28 Oct 2026, 12:52 am
FDC Limited Reports Robust Q2 FY27 With PAT Surging 72.9% YoY FDC Limited reported consolidated Q2 FY27 revenue of Rs. 572 crores, up 21.0% YoY, driven by a 22.6% YoY rise in Domestic Formulations to Rs. 467 crores and a 28.5% YoY rise in International Formulations to Rs. 75 crores (US up 109.7%). EBITDA jumped 90.2% YoY to Rs. 64 crores with margins expanding 410 bps to 11.2%. Net profit rose 72.9% YoY to Rs. 49 crores, yielding an EPS of Rs. 3.01. API sales contracted 4.8% YoY to Rs. 28 crores.
FDC Limited has informed the Exchange regarding Outcome of Board Meeting held on October 27, 2026.
Outcome · 28 Oct 2026, 12:00 am
Outcome of the Board Meeting held today i.e. Tuesday, October 27, 2026
Outcome · 27 Oct 2026, 11:37 pm
FDC Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 57,214 (+21.0% YoY | -14.3% QoQ) ■ EBITDA: 6,429 (+90.2% YoY | -55.0% QoQ) ■ EBITDA Margin (%): 11.2 (+409 bps YoY | -1018 bps QoQ) ■ PAT: 4,906 (+72.9% YoY | -63.0% QoQ) ■ EPS (INR): 3.01 (+72.0% YoY | -63.0% QoQ)
FDC LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Buyback/Other business.
Intimation · 27 Oct 2026, 5:30 am
FDC LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Buyback/Other business.
Intimation · 27 Oct 2026, 5:30 am
FDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve This is to inform you that a meeting of ....
Intimation · 27 Oct 2026, 5:30 am
FDC Board to Consider Q2 Results and Share Buyback on 27th Oct'26 FDC Limited's Board of Directors is scheduled to meet on 27th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the board will evaluate a proposal for the buyback of fully paid-up equity shares via the tender offer route, including deciding on the buyback size, price, and related terms. The company's insider trading window remains closed until 48 hours after the declaration of the financial results.
To consider buyback for equity shares
Intimation · 27 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 27 Oct 2026, 5:30 am
Disclosure of Voting results of the 86th Annual general Meeting held on 24th September, 2026 along with the Scrutinizer''s Report.
Annual General Meeting · 28 Sept 2026, 3:30 pm
Proceedings of the 86th Annual General Meeting held on Thursday, 24th September 2026.
Annual General Meeting · 24 Sept 2026, 8:31 pm
This is to inform you that a typographical error has occurred in the notice of the 86th AGM for FY 2025-26. The cutoff date for e-voting shall be read as September 17, 2026, instead of ....
Annual General Meeting · 17 Sept 2026, 10:46 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nandan Mohan Chandavarkar
Acquisition/ Disposal of Shares · 03 Sept 2026, 3:01 pm
BRSR for FY 2025-26
Others (Uncategorized) · 02 Sept 2026, 2:11 am
Annual Report for FY 2025-26
Others (Uncategorized) · 02 Sept 2026, 12:10 am
Please find enclosed Notice of 86th Annual General meeting for the FY 2025-26
Annual General Meeting · 01 Sept 2026, 10:18 pm
Announcement under Regulation 30
Others (Uncategorized) · 27 Aug 2026, 11:01 pm
FDC Obtains Interim Stay from Delhi High Court on FSSAI Notice The Delhi High Court granted an interim stay on 26 Aug'26 for a FSSAI notice against FDC Limited, related to the mislabeling of a product as an "electrolyte drink". The company has been granted eight months to sell its existing stock and implement required label changes. FDC stated this development has no material adverse financial or operational impact on the company. The original issue relates to a stock seizure by FSSAI Maharashtra, previously disclosed on 04 Jun'26.
This is to inform you that the company''s Subsidiary, FDC International Ltd., has received Marketing Authorisation from the MHRA, UK, for Atropine 1.0% w/v Eye Drops, Solution.
Others (Uncategorized) · 13 Aug 2026, 7:53 pm
FDC Subsidiary Secures UK MHRA Approval for Atropine Eye Drops FDC Limited announced on 13 Aug'26 that its subsidiary, FDC International Limited, has received Marketing Authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The approval is for Atropine 1.0% w/v Eye Drops, Solution. This regulatory milestone permits the marketing of the product within the United Kingdom, marking an expansion of the company's footprint in the region's ophthalmic market.